J M Reimund1, C Hirth, C Koehl, R Baumann, B Duclos. 1. Service d'Hépato-Gastroentérologie et d'Assistance Nutritive, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Strasbourg, France.
Abstract
BACKGROUND AND AIMS: As reactive oxygen has been demonstrated to participate in immune genes transcription, the aim of this study was to examine the relationship between systemic concentrations of several antioxidants and markers of inflammatory and immune activation in patients with Crohn's disease (CD). METHODS: In 26 CD patients and 15 controls we compared plasma selenium and zinc concentrations, erythrocyte glutathione peroxidase (GSHPx) and superoxide dismutase activities, as well as erythrocyte sedimentation rate (ESR), C-reactive protein, tumor necrosis factor-alpha, interleukin-6, blood neopterin and soluble receptors of interleukin-2 (sIL-2R), and examined the link between these parameters. RESULTS: Selenium concentration and GSHPx activity were decreased in CD patients (54.5 +/- 3.2 vs 79 ± 2.2 microg/l, P<< 0.05; 28 +/- 1.6 vs 38 +/- 2.6 IU/g Hb, P<< 0.05) and positively correlated to each other's (r= 0.59, P<< 0.01). TNF-alpha was significantly increased in patients (18 +/- 2.6 vs 5 +/- 0.6 pg/ml;P<< 0.001), negatively correlated to GSHPx activity (r= -0.56, P<< 0.05) and selenium concentration (r= -0.72, P<< 0.001), and positively to neopterin and sIL-2R concentrations. Selenium showed negative correlation with sIL-2R (r= -0.83, P<< 0.0001) and ESR. CONCLUSIONS: In CD patients low selenium concentration may participate in reduced GSHPx activity facilitating inflammatory and immune activation. In these patients, selenium monitoring and, if needed, supplementation may be of therapeutical interest. Copyright 2000 Harcourt Publishers Ltd.
BACKGROUND AND AIMS: As reactiveoxygen has been demonstrated to participate in immune genes transcription, the aim of this study was to examine the relationship between systemic concentrations of several antioxidants and markers of inflammatory and immune activation in patients with Crohn's disease (CD). METHODS: In 26 CDpatients and 15 controls we compared plasma selenium and zinc concentrations, erythrocyte glutathione peroxidase (GSHPx) and superoxide dismutase activities, as well as erythrocyte sedimentation rate (ESR), C-reactive protein, tumor necrosis factor-alpha, interleukin-6, blood neopterin and soluble receptors of interleukin-2 (sIL-2R), and examined the link between these parameters. RESULTS:Selenium concentration and GSHPx activity were decreased in CDpatients (54.5 +/- 3.2 vs 79 &plusmn 2.2 microg/l, P<< 0.05; 28 +/- 1.6 vs 38 +/- 2.6 IU/g Hb, P<< 0.05) and positively correlated to each other's (r= 0.59, P<< 0.01). TNF-alpha was significantly increased in patients (18 +/- 2.6 vs 5 +/- 0.6 pg/ml;P<< 0.001), negatively correlated to GSHPx activity (r= -0.56, P<< 0.05) and selenium concentration (r= -0.72, P<< 0.001), and positively to neopterin and sIL-2R concentrations. Selenium showed negative correlation with sIL-2R (r= -0.83, P<< 0.0001) and ESR. CONCLUSIONS: In CDpatients low selenium concentration may participate in reduced GSHPx activity facilitating inflammatory and immune activation. In these patients, selenium monitoring and, if needed, supplementation may be of therapeutical interest. Copyright 2000 Harcourt Publishers Ltd.
Authors: Gary E Wild; Laurie Drozdowski; Carmela Tartaglia; M Tom Clandinin; Alan B R Thomson Journal: World J Gastroenterol Date: 2007-01-07 Impact factor: 5.742
Authors: Valérie Marcil; Emile Levy; Devendra Amre; Alain Bitton; Ana Maria Guilhon de Araújo Sant'Anna; Andrew Szilagy; Daniel Sinnett; Ernest G Seidman Journal: Inflamm Bowel Dis Date: 2019-07-17 Impact factor: 5.325
Authors: Caitlyn W Barrett; Kshipra Singh; Amy K Motley; Mary K Lintel; Elena Matafonova; Amber M Bradley; Wei Ning; Shenika V Poindexter; Bobak Parang; Vishruth K Reddy; Rupesh Chaturvedi; Barbara M Fingleton; Mary K Washington; Keith T Wilson; Sean S Davies; Kristina E Hill; Raymond F Burk; Christopher S Williams Journal: PLoS One Date: 2013-07-04 Impact factor: 3.240